Expression of anti-CTLA-4 (mRP2) further improved anti-tumor activity in the mouse A20 model, and combining mRP1 with anti-PD-1 antibody significantly improved the inhibition of non-injected tumors [61]. The gene discussed is CTLA4; the disease is neoplasm.